<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ironwood Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc</link>
<description>Latest news and press releases for Ironwood Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 11:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ironwood-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835852978dffbe2df0fd668.webp</url>
<title>Ironwood Pharmaceuticals Inc</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc</link>
</image>
<item>
<title>Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-to-share-real-world-hcp-perspectives-on-burden-of-total-parenteral-nutrition-in-short-bowel-syndrome-sbs-at-digestive-disease-weekr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-to-share-real-world-hcp-perspectives-on-burden-of-total-parenteral-nutrition-in-short-bowel-syndrome-sbs-at-digestive-disease-weekr-2026</guid>
<pubDate>Thu, 23 Apr 2026 11:05:00 GMT</pubDate>
<description>BOSTON, April 23, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced today that the company will present data from its LANDMARK survey during the 2026 Digestive Disease Week® (DDW) meeting being held from May 2-5 in Chicago, IL. The data will spotlight healthcare professional (HCP) insights on the burden of total parenteral nutrition (TPN) for</description>
</item>
<item>
<title>Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-results-achieves-2025-financial-guidance-and-reiterates-strong-2026-outlook</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-results-achieves-2025-financial-guidance-and-reiterates-strong-2026-outlook</guid>
<pubDate>Wed, 25 Feb 2026 12:05:00 GMT</pubDate>
<description>BOSTON, February 25, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full‑year 2025 results and recent business performance.</description>
</item>
<item>
<title>Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-to-host-fourth-quarter-and-full-year-2025-investor-update-call</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-to-host-fourth-quarter-and-full-year-2025-investor-update-call</guid>
<pubDate>Wed, 18 Feb 2026 21:21:00 GMT</pubDate>
<description>BOSTON, February 18, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its fourth quarter and full year 2025 investor update conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 25, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 8188306. To access the webcast, please visit the Investors & Media section of I</description>
</item>
<item>
<title>Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-maintains-fy-2025-financial-guidance-and-announces-fy-2026</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-maintains-fy-2025-financial-guidance-and-announces-fy-2026</guid>
<pubDate>Fri, 02 Jan 2026 05:00:00 GMT</pubDate>
<description>- Expects full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300</description>
</item>
<item>
<title>Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-reports-strong-third-quarter-2025-results-raises-full-year</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-reports-strong-third-quarter-2025-results-raises-full-year</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>– LINZESS® (linaclotide) U.S. net sales of $315 million in Q3 2025, an increase of 40% year-over-year; EUTRx demand growth increased 12% year-over-year – –</description>
</item>
<item>
<title>EchoStor Technologies Bolsters C-Suite with Appointment of Cale Anjoorian as Chief Information Officer</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/echostor-technologies-bolsters-c-suite-with-appointment-of-cale-anjoorian-as-chief-information-officer</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/echostor-technologies-bolsters-c-suite-with-appointment-of-cale-anjoorian-as-chief-information-officer</guid>
<pubDate>Mon, 25 Aug 2025 14:26:00 GMT</pubDate>
<description>EchoStor Technologies, fresh off its recognition on the 2025 Inc. 5000 List and multiple CRN honors, today announced the appointment of Cale Anjoorian as Chief Information Officer. The strategic hire underscores EchoStor's continued momentum and commitment to assembling best-in-class technology leadership as the company scales its enterprise offerings and expands its market presence.</description>
</item>
<item>
<title>Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-reports-second-quarter-2025-results-maintains-full-year-2025</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-reports-second-quarter-2025-results-maintains-full-year-2025</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>– LINZESS® (Iinaclotide) U.S. net sales of $248 million in Q2 2025; EUTRx demand growth of 10% year-over-year – – Plans to align with FDA on confirmatory</description>
</item>
<item>
<title>Ironwood Pharmaceuticals Reports First Quarter 2025 Results</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-reports-first-quarter-2025-results-2025-05-07</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-reports-first-quarter-2025-results-2025-05-07</guid>
<pubDate>Wed, 07 May 2025 04:00:00 GMT</pubDate>
<description>– On track to achieve FY 2025 financial guidance; raised adjusted EBITDA guidance to greater than $105 million for 2025 – – LINZESS® (linaclotide) EUTRx</description>
</item>
<item>
<title>Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-participate-citizens-life-sciences-conference-2025-04-30</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-participate-citizens-life-sciences-conference-2025-04-30</guid>
<pubDate>Wed, 30 Apr 2025 04:00:00 GMT</pubDate>
<description>BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens</description>
</item>
<item>
<title>Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-reiterates-full-year-2025-linzess-us-net-sales-guidance-and</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-reiterates-full-year-2025-linzess-us-net-sales-guidance-and</guid>
<pubDate>Fri, 25 Apr 2025 04:00:00 GMT</pubDate>
<description>– Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million – – LINZESS (Iinaclotide) EUTRx</description>
</item>
<item>
<title>Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-present-real-world-data-digestive-disease-weekr-2025</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-present-real-world-data-digestive-disease-weekr-2025</guid>
<pubDate>Tue, 22 Apr 2025 04:00:00 GMT</pubDate>
<description>– Additional presentations will highlight results from Phase III study evaluating linaclotide in pediatric patients aged 7-17 years with irritable bowel</description>
</item>
<item>
<title>Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-provides-clinical-and-regulatory-update-apraglutide-2025-04</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-provides-clinical-and-regulatory-update-apraglutide-2025-04</guid>
<pubDate>Mon, 14 Apr 2025 04:00:00 GMT</pubDate>
<description>– Feedback from recent FDA interaction indicates that a confirmatory Phase 3 trial evaluating apraglutide in SBS-IF is needed to seek approval – – Company</description>
</item>
<item>
<title>Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-announces-receipt-nasdaq-non-compliance-notification</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-announces-receipt-nasdaq-non-compliance-notification</guid>
<pubDate>Thu, 27 Mar 2025 04:00:00 GMT</pubDate>
<description>BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (the “Company”) (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing</description>
</item>
<item>
<title>Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-results-achieves</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-results-achieves</guid>
<pubDate>Thu, 27 Feb 2025 05:00:00 GMT</pubDate>
<description>– Announced positive data from open-label extension study demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time –</description>
</item>
<item>
<title>Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-host-fourth-quarter-and-full-year-2024-investor-update-call</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-host-fourth-quarter-and-full-year-2024-investor-update-call</guid>
<pubDate>Thu, 20 Feb 2025 05:00:00 GMT</pubDate>
<description>BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2024 investor update</description>
</item>
<item>
<title>Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-initiates-apraglutide-nda-submission-highlights-compelling</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-initiates-apraglutide-nda-submission-highlights-compelling</guid>
<pubDate>Wed, 29 Jan 2025 05:00:00 GMT</pubDate>
<description>– Data from open label extension study of apraglutide demonstrate further increase in patients achieving enteral autonomy – – Initiated rolling NDA</description>
</item>
<item>
<title>Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-participate-piper-sandler-36th-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-participate-piper-sandler-36th-annual-healthcare-conference</guid>
<pubDate>Tue, 26 Nov 2024 05:00:00 GMT</pubDate>
<description>BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Piper</description>
</item>
<item>
<title>Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-participate-jefferies-london-healthcare-conference-2024-11</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-participate-jefferies-london-healthcare-conference-2024-11</guid>
<pubDate>Wed, 13 Nov 2024 05:00:00 GMT</pubDate>
<description>BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial</description>
</item>
<item>
<title>Ironwood Pharmaceuticals Reports Third Quarter 2024 Results</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-reports-third-quarter-2024-results-2024-11-07</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/ironwood-pharmaceuticals-reports-third-quarter-2024-results-2024-11-07</guid>
<pubDate>Thu, 07 Nov 2024 05:00:00 GMT</pubDate>
<description>– LINZESS® (Iinaclotide) EUTRx prescription demand growth of 13% year-over-year – – Remains on track to complete apraglutide NDA submission in Q1 2025 – –</description>
</item>
<item>
<title>Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024</title>
<link>https://6ix.com/company/ironwood-pharmaceuticals-inc/news/once-weekly-apraglutide-showed-consistent-treatment-effect-across-baseline</link>
<guid isPermaLink="true">https://6ix.com/company/ironwood-pharmaceuticals-inc/news/once-weekly-apraglutide-showed-consistent-treatment-effect-across-baseline</guid>
<pubDate>Mon, 28 Oct 2024 04:00:00 GMT</pubDate>
<description>– New safety and tolerability data show high treatment compliance with apraglutide, low incidence of injection site reactions and adverse events associated</description>
</item>
</channel>
</rss>